Background illustration for clinical trials search

Merck Clinical Trials

Find clinical trials for Merck. Search for Merck clinical trials in different cities and states across the United States.

Filter

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

for
Human Immunodeficiency Virus (HIV) Infection
Location: Atlanta GA
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 11

Code: NCT04375800

Phase 2, Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

for
Carcinoma, Non-Small-Cell Lung
Location: Lebanon NH, Philadelphia PA, Columbus OH, Houston TX,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04165070

Phase 1, Phase 2, Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

for
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor,
Location: Boston MA, Baltimore MD, Bethesda MD, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 12+

Code: NCT04924075

Phase 2, Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Norwich CT, Hackensack NJ, Albany NY, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06136559

Phase 3, Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

for
DLBCL, Diffuse Large B-Cell Lymphoma
Location: Valhalla NY, Horsham PA, Boca Raton FL, Hialeah FL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05139017

Phase 2, Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

for
Crohn Disease, Colitis, Ulcerative
Location: Bristol CT, New York NY, Charlottesville VA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0+

Code: NCT06651281

Phase 3, Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

for
Non-cystic Fibrosis Bronchiectasis
Location: Boston MA, New York NY, Philadelphia PA,
Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Sex: All

Age: 18 - 70+

Code: NCT06559150

Phase 2, Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for
Triple-Negative Breast Cancer
Location: Halifax, Moncton, Rimouski, Farmington CT, New Haven CT,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06393374

Phase 3, Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

for
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma,
Location: East Syracuse NY, Pittsburgh PA, Grand Rapids MI,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06445972

Phase 1, Phase 2, Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Scarborough ME, Providence RI, New Haven CT, Mineola NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06824467

Phase 3, Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

for
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma,
Location: Boston MA, New York NY, Chicago IL, Fargo ND,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 17

Code: NCT02332668

Phase 1, Phase 2, Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

for
Pulmonary Arterial Hypertension
Location: Philadelphia PA, Washington D.C. DC, Cincinnati OH,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 1 - 17

Code: NCT05587712

Phase 2, Recruiting

SW-682 in Advanced Solid Tumors

for
Advanced Solid Tumor, Mesothelioma, Malignant
Location: Cleveland OH, Houston TX, Dallas TX, Scottsdale AZ,
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Sex: All

Age: 18+

Code: NCT06251310

Phase 1, Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

for
Prostatic Neoplasms, Castration-Resistant
Location: Quebec, Montreal, Miami FL, Cleveland OH, Milwaukee WI,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06353386

Phase 1, Phase 2, Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

for
Non-small Cell Lung Cancer
Location: Halifax, Stamford CT, Trois-Rivieres, Albany NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06345729

Phase 3, Recruiting

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

for
Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
Location: New York NY, Philadelphia PA, Winston-Salem NC,
Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Sex: All

Age: 18+

Code: NCT06163430

Phase 1, Phase 2, Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

for
Urinary Bladder Neoplasms,
Location: Moncton, Sherbrooke, New York NY, Bala-Cynwyd PA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06833073

Phase 2, Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

for
Thrombocythemia, Essential, Primary Myelofibrosis,
Location: Durham NC, Pittsburgh PA, Columbus OH, Ann Arbor MI
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06351631

Phase 3, Recruiting

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

for
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma,
Location: East Syracuse NY, Pittsburgh PA, Grand Rapids MI,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06469944

Phase 1, Phase 2, Recruiting

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

for
Breast Neoplasms, Breast Cancer
Location: Boston MA, New Brunswick NJ, Montreal, Fairfax VA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06686394

Phase 1, Phase 2, Recruiting